Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARCT Arcturus Therapeutics	$12.20 -4.7%	$11.37	$8.04 ▼ $45.00	$330.88M	2.36	451,437 shs	353,268 shs
CDTX Cidara Therapeutics	$24.28 -5.5%	$20.72	$10.14 ▼ $28.42	$304.64M	0.86	78,419 shs	163,459 shs
CYRX Cryoport	$6.04 -2.9%	$5.93	$4.58 ▼ $11.64	$302.83M	1.92	544,154 shs	253,099 shs
SNTI Senti Biosciences	$3.20 +4.9%	$3.43	$1.52 ▼ $16.94	$83.46M	2.31	805,485 shs	24,854 shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARCT Arcturus Therapeutics	-4.69%	+4.72%	-3.56%	-31.34%	-62.32%
CDTX Cidara Therapeutics	-5.53%	-4.78%	+10.87%	+13.09%	+96.76%
CYRX Cryoport	-2.89%	-9.58%	+8.05%	-2.89%	-47.57%
SNTI Senti Biosciences	+4.92%	+0.63%	-27.77%	-19.19%	-12.16%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARCT Arcturus Therapeutics	2.9759 of 5 stars	4.6	0.0	0.0	3.3	2.5	0.6
CDTX Cidara Therapeutics	4.384 of 5 stars	4.6	4.0	4.6	2.1	0.8	0.0
CYRX Cryoport	3.0414 of 5 stars	4.4	1.0	0.0	3.2	2.5	0.6
SNTI Senti Biosciences	2.1378 of 5 stars	3.5	3.0	0.0	1.7	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARCT Arcturus Therapeutics	3.13	Buy	$57.80	373.77% Upside
CDTX Cidara Therapeutics	3.22	Buy	$41.86	72.39% Upside
CYRX Cryoport	2.71	Moderate Buy	$11.00	82.12% Upside
SNTI Senti Biosciences	3.00	Buy	$12.00	275.00% Upside

Current Analyst Ratings Breakdown

Latest SNTI, CDTX, CYRX, and ARCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/23/2025	CDTX Cidara Therapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$31.00 ➝ $35.00
5/23/2025	CDTX Cidara Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$35.00
5/16/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$35.00 ➝ $50.00
5/14/2025	ARCT Arcturus Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$50.00 ➝ $45.00
5/13/2025	ARCT Arcturus Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy
5/13/2025	ARCT Arcturus Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$68.00 ➝ $66.00
5/9/2025	CDTX Cidara Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$33.00 ➝ $35.00
5/9/2025	CDTX Cidara Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Market Outperform ➝ Market Outperform	$46.00 ➝ $47.00
5/8/2025	CYRX Cryoport	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$11.00 ➝ $11.00
5/5/2025	CYRX Cryoport	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Equal Weight ➝ Equal Weight	$8.00 ➝ $7.00
5/2/2025	SNTI Senti Biosciences	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 5/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARCT Arcturus Therapeutics	$131.27M	2.52	N/A	N/A	$10.42 per share	1.17
CDTX Cidara Therapeutics	$302K	1,008.75	N/A	N/A	($1.82) per share	-13.34
CYRX Cryoport	$232.13M	1.30	$0.36 per share	16.95	$9.45 per share	0.64
SNTI Senti Biosciences	$2.56M	32.60	N/A	N/A	$15.02 per share	0.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARCT Arcturus Therapeutics	-$29.73M	-$2.53	N/A	N/A	N/A	-36.39%	-22.39%	-14.81%	8/4/2025 (Estimated)
CDTX Cidara Therapeutics	-$22.93M	-$29.47	N/A	N/A	N/A	-289.05%	-69.64%	-33.73%	8/11/2025 (Estimated)
CYRX Cryoport	-$99.59M	-$2.34	N/A	N/A	N/A	-70.08%	-13.35%	-6.43%	8/5/2025 (Estimated)
SNTI Senti Biosciences	-$71.06M	-$10.84	N/A	N/A	N/A	N/A	-154.84%	-77.42%	8/12/2025 (Estimated)

Latest SNTI, CDTX, CYRX, and ARCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/12/2025	Q1 2025	ARCT Arcturus Therapeutics	-$1.58	-$0.52	+$1.06	-$0.52	$25.64 million	$29.38 million
5/8/2025	Q1 2025	CDTX Cidara Therapeutics	-$5.45	-$1.66	+$3.79	-$1.66	N/A	N/A
5/7/2025	Q1 2025	CYRX Cryoport	-$0.23	-$0.22	+$0.01	-$0.28	$56.19 million	$41.04 million
5/6/2025	Q1 2025	SNTI Senti Biosciences	-$0.56	-$1.41	-$0.85	-$1.41	$1.30 million	$1.30 million
3/20/2025	Q4 2024	SNTI Senti Biosciences	-$3.13	-$0.67	+$2.46	-$0.67	$2.80 million	$5.86 million
3/6/2025	Q4 2024	ARCT Arcturus Therapeutics	-$0.33	-$1.11	-$0.78	-$1.11	$44.64 million	$22.77 million
3/6/2025	Q4 2024	CDTX Cidara Therapeutics	-$5.28	-$5.38	-$0.10	-$5.37	N/A	N/A
3/4/2025	Q4 2024	CYRX Cryoport	-$0.33	-$0.42	-$0.09	-$0.42	$58.71 million	$59.53 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARCT Arcturus Therapeutics	$0.71	5.86%	N/A	N/A	N/A
CDTX Cidara Therapeutics	N/A	N/A	N/A	N/A	N/A
CYRX Cryoport	N/A	N/A	N/A	N/A	N/A
SNTI Senti Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARCT Arcturus Therapeutics	N/A	4.76	4.76
CDTX Cidara Therapeutics	N/A	3.54	3.54
CYRX Cryoport	0.48	5.70	5.32
SNTI Senti Biosciences	N/A	1.92	1.92

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARCT Arcturus Therapeutics	94.54%
CDTX Cidara Therapeutics	35.82%
CYRX Cryoport	92.90%
SNTI Senti Biosciences	25.73%

Insider Ownership

Company	Insider Ownership
ARCT Arcturus Therapeutics	16.60%
CDTX Cidara Therapeutics	3.89%
CYRX Cryoport	10.00%
SNTI Senti Biosciences	3.12%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARCT Arcturus Therapeutics	180	27.12 million	22.94 million	Optionable
CDTX Cidara Therapeutics	90	12.55 million	6.51 million	No Data
CYRX Cryoport	1,020	50.14 million	44.44 million	Optionable
SNTI Senti Biosciences	4	26.08 million	4.30 million	Not Optionable

SNTI, CDTX, CYRX, and ARCT Headlines

Recent News About These Companies

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

May 24 at 9:00 AM | accessnewswire.com

Senti Biosciences Receives Additional $1 Million from CIRM to Support Clinical Development of SENTI-202 Cell Therapy

May 23 at 9:16 PM | nasdaq.com

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Initiates Investigation into Senti Biosciences Inc

May 23 at 1:15 PM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Investors to Connect

May 23 at 10:00 AM | accessnewswire.com

Senti Bio to Present at LIVE! with Webull Corporate Connect: Virtual Biotech Investment Webinar

May 22 at 4:05 PM | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Stockholders to Inquire about Securities Investigation

May 22 at 10:00 AM | accessnewswire.com

Senti Bio Receives Additional $1.0 Million Tranche from California Institute for Regenerative Medicines (CIRM) Grant for Advancing Clinical Development of SENTI-202

May 22 at 8:30 AM | globenewswire.com

Bronstein, Gewirtz & Grossman, LLC Encourages Senti Biosciences, Inc. (SNTI) Investors to Inquire about Securities Investigation

May 21 at 10:00 AM | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

May 21 at 9:00 AM | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Investors to Reach Out

May 20, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

May 20, 2025 | prnewswire.com

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm

May 20, 2025 | prnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

May 19, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Reach Out

May 19, 2025 | accessnewswire.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Senti Biosciences, Inc. (SNTI) And Encourages Stockholders to Connect

May 18, 2025 | accessnewswire.com

Senti Biosciences, Inc. (SNTI) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation

May 16, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

May 16, 2025 | accessnewswire.com

SNTI Investors Have Opportunity to Join Senti Biosciences, Inc. Fraud Investigation with the Schall Law Firm

May 15, 2025 | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

May 14, 2025 | accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Senti Biosciences, Inc. - SNTI

May 13, 2025 | globenewswire.com

Senti Biosciences (SNTI) to Release Earnings on Thursday

May 5, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SNTI, CDTX, CYRX, and ARCT Company Descriptions

Arcturus Therapeutics NASDAQ:ARCT

$12.20 -0.60 (-4.69%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$12.26 +0.06 (+0.46%)

As of 05/23/2025 04:37 PM Eastern

Arcturus Therapeutics Holdings Inc., a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA. The company is developing ARCT-810 (LUNAR-OTC), a mRNA-based therapeutic candidate, which is in Phase 2 clinical trial for treating ornithine transcarbamylase deficiency; and ARCT-154 (LUNAR-COV19), a mRNA vaccine candidate that is in Phase 3 arm of a Phase 1/2/3 study in Vietnam for the treatment of COVID-19, as well as ARCT-032 (LUNAR-CF), a mRNA therapeutic candidate for cystic fibrosis. Its product pipeline includes, ARCT-2301 for bivalent: ancestral/omicron which is in Phase 3; ARCT-2303 for monovalent that is in Phase 3; ARCT-2138 for quadrivalent which is in Phase 1; and LUNAR-FLU which is in pre-clinical trial. Arcturus Therapeutics Holdings Inc. was founded in 2013 and is headquartered in San Diego, California.

Cidara Therapeutics NASDAQ:CDTX

$24.28 -1.42 (-5.53%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$24.35 +0.07 (+0.29%)

As of 05/23/2025 05:43 PM Eastern

Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.

Cryoport NASDAQ:CYRX

$6.04 -0.18 (-2.89%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$6.04 0.00 (0.00%)

As of 05/23/2025 04:04 PM Eastern

Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services. It also provides CRYOGENE, an unparalleled solution that offers pre-clinical temperature-controlled biological materials management services comprising specimen storage, processing, collection, and retrieval; CRYOPD, a temperature-controlled logistics solution, which include temperature-controlled packaging and transport solutions from cryogenic temperature to controlled ambient; and IntegriCell services that comprise apheresis/leukapheresis collection, Cryoshuttle transportation, cryo-process optimization and processing services. In addition, the company offers MVE Biological Solutions' Fusion cryogenic system, a self-sustaining cryogenic freezer; MVE Biological Solutions' Vario cryogenic system, a cryogenic freezer system that supports temperatures between -20°C and -150°C; Cryoport Cryoshuttle provides clients with dedicated local transportation support; and Tec4Med. Further, it provides biological specimen cryopreservation storage and maintenance; archiving, monitoring, tracking, receipt, and delivery of samples; frozen biological specimens transportation; and incoming and outgoing biological specimens management; and short-term logistics and engineering consulting services. Cryoport, Inc. was founded in 1999 and is headquartered in Brentwood, Tennessee.

Senti Biosciences NASDAQ:SNTI

$3.20 +0.15 (+4.92%)

Closing price 05/23/2025 04:00 PM Eastern

Extended Trading

$3.20 -0.01 (-0.16%)

As of 05/23/2025 07:58 PM Eastern

Senti Biosciences, Inc. operates as a preclinical biotechnology company that develops next-generation cell and gene therapies engineered with its gene circuit platform technologies for various diseases. Its lead product candidates utilize allogeneic chimeric antigen receptor natural killer (CAR-NK) cells outfitted with its gene circuit technologies in various oncology indications. The company product candidates include SENTI-202, a Logic Gated OR+NOT off-the-shelf CAR-NK cell therapy designed to target and eliminate cancer cells while sparing the healthy bone marrow; and SENTI-301A for the treatment of hepatocellular carcinoma. It also develops SENTI-401, a Logic Gated off-the-shelf CAR-NK cell therapy designed to target and eliminate colorectal cancer/CRC cells. In addition, the company develops Tumor-Associated Antigen and Protective Antigen Paired Discovery Platform to select and validate NOT GATE antigen candidates and identify tumor-associated antigens in cancer cells. The company has a strategic collaboration with Celest Therapeutics (Shanghai) Co. Ltd for the clinical development of SENTI-301A to treat solid tumors. Senti Biosciences, Inc. was incorporated in 2016 and is headquartered in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time